Limited Use Note(s) |
|
TOBRAMYCIN28mg Inh Pd-Cap
| Reason For Use Code | Clinical Criteria |
|---|---|
| 472 | For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections. Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle. |
| LU Authorization Period: Indefinite. |